ME Therapeutics Holdings, Inc.

As of May 31, 2026, ME THERAPEUTICS HLDGS INC. has 30.05M shares outstanding.

As of May 31, 2026, ME THERAPEUTICS HLDGS INC. maintains a current ratio of 3.91, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.18, indicating elevated leverage, while an interest coverage ratio of -179.29 demonstrates limited ability to service its debt obligations.

Over the twelve months ended May 31, 2026, ME THERAPEUTICS HLDGS INC. posted a negative return on equity (ROE) of -111.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -98.27, reflecting losses generated across the asset base.

As of the close on September 9, 2026, ME THERAPEUTICS HLDGS INC.'s stock has declined approximately 43.34% over the past 52 weeks.

Over the twelve months ended May 31, 2026, ME THERAPEUTICS HLDGS INC. generated - - in revenue and converted that into -1.00M in net income, yielding earnings per share of -0.03. EBITDA reached -1.05M, while operating income came in at -1.01M.

As of May 31, 2026, ME THERAPEUTICS HLDGS INC. holds 388,978.47 in cash and equivalents against 19,543.25 in total debt, resulting in a net debt position of -347,290.65. Total book value stands at 467,698.83, with working capital of 318,114.99 providing operational flexibility.

ME THERAPEUTICS HLDGS INC. produced -880,446.60 in operating cash flow over the twelve months ended May 31, 2026. After subtracting -54,967.74 in capital expenditures, free cash flow totaled -935,414.34 - equivalent to -0.03 per share.